Inflammation drug developer HCW Biologics' Q2 net loss widens
HCWB•Analyst coverage
- The one available analyst rating on the shares is "buy"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for HCW Biologics Inc is $30.00, about 925.6% above its August 13 closing price of $2.93
Q2 revenue rises, but net loss widens
- US biopharma firm's Q2 revenue rose yr/yr, driven by licensing agreement completion
- Company posted higher Q2 net loss compared to prior year period
- Company raised $5.6 mln in equity financings during the quarter
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Loss Per Basic Share | $11.58 |
Going-concern warning and operating expense drivers
-
Company says substantial doubt exists about ability to continue for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support
-
LICENSING AGREEMENT - Q2 revenue increase was driven by completion of exclusive, worldwide licensing agreement with Beijing Trimmune Biotech and related post-transfer services
